Gastric & duodenal ulcer, reflux esophagitis, prevention of recurrence of gastric or duodenal ulcer during low-dose aspirin or NSAIDs administration. Adjunct to H. pylori eradication.
AdultGastric & duodenal ulcer 20 mg once daily, up to 8 wk for gastric ulcer & up to 6 wk for duodenal ulcer. Reflux esophagitis 20 mg once daily for up to 4 wk or if necessary, up to 8 wk. Maintenance of reflux esophagitis healing 10 mg once daily until 24 wk. Prevention of recurrence of gastric or duodenal ulcer during low-dose aspirin or NSAIDs administration 10 mg once daily. Adjunct to H. pylori eradication 20 mg vonoprazan + amoxicillin hydrate + clarithromycin twice daily for 7 days. Alternatively, 20 mg vonoprazan + amoxicillin hydrate + metronidazole twice daily for 7 days may be used if other treatment fails.
Close observation by endoscopy should be made during long-term treatment. Administer only in patients who repeat recurrence & recrudescence of reflux esophagitis. Discontinue treatment in patients who have evidence of liver function abnormalities or if they develop signs or symptoms suggestive of liver dysfunction. Concomitant use w/ drugs for which absorption is dependent on acidic intragastric pH. Does not preclude gastric malignancy. Increased risk of GI infection caused by Clostridium difficile in patients receiving PPIs. Benign gastric polyp in long-term administration of PPIs. Increased risk for osteoporosis-related fractures of the hip, wrist or spine; especially increased in patients receiving high dose or long term (≥1 yr) treatment. Renal & hepatic disorders. Not to be administered to women who are or may be pregnant. Avoid use during lactation. Childn <18 yr. Elderly.
May interfere w/ the absorption of drugs whose bioavailability is pH-dependent (eg, atazanavir & nelfinavir). May promote or inhibit absorption of concomitant drugs which absorption is dependent on acidic intragastric pH. May diminish effects of atazanavir sulfate & rilpivirine HCl; itraconazole, tyrosine kinase inhibitors (eg, gefitinib, nilotinib, erlotinib), nelfinavir mesylate. May increase blood conc w/ CYP3A4 inhibitors eg, clarithromycin. May enhance effects of digoxin & methyldigoxin.
A02BC08 - vonoprazan ; Belongs to the class of potassium-competitive acid blocker. Used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).
Sign Out
